Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) - REMAP-CAP

niversitair Medisch Centrum Utrecht0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2024年9月9日

研究概览

暂无简介。

•General REMAP-CAP:
•1. Adult patient admitted to an ICU for acute severe CAP within 48 hours of
•hospital admission with
•a. symptoms or signs or both that are consistent with lower respiratory tract
•infection AND
•b. Radiological evidence of new onset infiltrate of infective origin (in
•patients with pre-existing radiological changes, evidence of new infiltrate)
•2. Up to 48 hours after ICU admission, receiving organ support with one or more
•a. Non-invasive or invasive ventilatory support;
•b. Receiving infusion of vasopressor or inotropes or both
•For the COVID-19 domains:
•1. COVID-19 infection is suspected by the treating clinician or has been
•confirmed by microbiological testing (i.e. PISOP stratum)
•2. Microbiological testing for SARS-CoV-2 infection of upper or lower
•respiratory tract secretions or both has occurred or is intended to occur
•If applicable, domain and/or intervention-specific inclusion criteria listed in

•General REMAP-CAP Exclusion Criteria:
•1. Healthcare-associated pneumonia:
•a. Prior to this illness, is known to have been an inpatient in any
•healthcare facility within the last 30 days
•b. Resident of a nursing home or long-term care facility.
•2. Death is deemed to be imminent and inevitable during the next 24
•hours AND one or more of the patient, substitute decision maker or
•attending physician are not committed to full active treatment.
•3. Previous participation in this REMAP within the last 90 days
•For subjects suspected or proven to have COVID-19, the 48 hour time window does
•not apply, due to the nature of the disease process.
•There are specific exclusion criteria (if needed) for every domain or
•intervention within a domain in the trial, listed in each DSA.

发起方

niversitair Medisch Centrum Utrecht